By World Longevity Clinics Editorial Team FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies

Stem Cell Therapy at Longevity Clinics: Why WLC Withdrew Its 2026 Ranking

WLC withdrew its 2026 stem-cell clinic ranking because the evidence did not support recommendations, prices, candidate profiles, or maintenance schedules. Here is what patients can verify instead.

stem cell therapy regenerative medicine FDA regulation patient safety

Correction, August 28, 2026: WLC has withdrawn the clinic and country ranking that previously appeared on this URL. The cited scientific review did not compare commercial clinics, verify prices or protocols, identify suitable longevity patients, or support maintenance schedules. Those claims have been removed.

Stem-cell research in aging and disease is a legitimate field. That does not make a cash-pay stem-cell program a proven longevity treatment, and it does not provide a defensible basis for naming the “best” clinic.

Why the ranking could not be supported

The previous article relied mainly on a 2023 review of clinical trials involving aging, frailty, and related conditions. It then extended that evidence into commercial decisions the review did not answer.

WLC could not substantiate:

  • a market-size claim tied specifically to longevity treatment;
  • a conclusion that allogeneic mesenchymal stromal cells are the preferred option for patients;
  • clinic, country, treatment-price, or medical-tourism rankings;
  • candidate profiles for preventive anti-aging treatment;
  • one-to-three infusion protocols or annual maintenance schedules;
  • claims that a commercial program improves longevity or reverses biological age.

A cell type appearing frequently in trials does not make it the best clinical choice. A phase 1 or phase 2 study in a defined disease population does not validate a general rejuvenation package for healthy adults.

What regulators say patients should check

The FDA’s regenerative-medicine patient guidance warns that many stem-cell, stromal vascular fraction, umbilical-cord, amniotic, Wharton’s jelly, and exosome products marketed to consumers are unapproved.

In the United States, FDA-approved stem-cell products are limited to blood-forming cells derived from umbilical cord blood for specified disorders affecting blood production. That is not approval for anti-aging, orthopedic, neurological, immune, or general longevity uses.

In the European Union, some manipulated cell products may fall under advanced-therapy medicinal-product rules. The relevant pathways can include central authorisation, an authorised clinical trial, or a narrow national hospital exemption. The WLC guide to EU ATMP rules explains the documentation each pathway should produce.

An entry on ClinicalTrials.gov, registration of a manufacturing facility, a physician’s involvement, or the word “experimental” does not by itself prove that a product is lawfully marketed or effective for the proposed use.

What to request before considering any cell product

Ask the provider for written answers and source documents covering:

  1. the exact product, cell type, donor source, processing, dose, and route;
  2. the diagnosis or indication being treated;
  3. the approval, trial, exemption, or other regulatory pathway in that jurisdiction;
  4. human evidence for the same product, route, population, and outcome;
  5. manufacturer, facility, donor screening, sterility, identity, potency, and traceability records;
  6. contraindications, known and plausible risks, and alternatives;
  7. the licensed clinician responsible for treatment and emergency escalation;
  8. adverse-event reporting and long-term follow-up;
  9. a dated, itemized quote including complication and follow-up costs.

Walk away if the clinic cannot identify the product, relies on testimonials as efficacy evidence, guarantees rejuvenation, or describes a commercial treatment as legal merely because it is offered in another country.

What WLC recommends now

WLC does not currently publish a ranking of longevity clinics for stem-cell therapy. Availability in a directory is a provider attribute, not evidence of approval, effectiveness, manufacturing quality, or suitability.

Use the multi-jurisdiction patient-safety guide to identify the relevant regulator. For European cell products, use the ATMP authorisation and hospital-exemption checklist.

This page remains available as a correction record while WLC reviews external search and backlink data. It should not be used to select a clinic or treatment.

This article is informational and does not provide medical or legal advice. Seek an independent specialist review before considering any unapproved or investigational regenerative product.